279.55
+1.40%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medicamen Biotech
Its shares trade on NSE under the ticker MEDICAMEQ.NS. It has been listed since 27 July 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹1.98bn and net income of ₹96.4m. At that date it held total assets of ₹3.72bn and shareholders' equity of ₹2.76bn.
Medicamen Biotech Ltd. engages in the manufacture and marketing of pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm is engaged in manufacturing of diverse range of pharmaceutical products oral solids, oral liquids, ointment for non-oncology products range and also produces tablets, capsule/lyohilized/dry powder injections for oncology product range. The company focuses on oncology therapeutics, and other generics. The firm manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The firm primarily focuses on oncology therapeutics. The company is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, and Pazopanib.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Jul 1995
- Employees
- 388
- Website
- medicamen.com ↗
Leadership
Pay as last reported
- Mr. Rahul BishnoiNon-Executive Chairman of the Board
- Mr. Rajesh MadanChief Executive Officer
- Mr. Chandan KumarChief Financial Officer
- Ms. Parul ChoudharyCompliance Officer, Company Secretary
- Mr. Ashwani SharmaWhole Time Director, since 2015
- Mr. Sanjay BansalNon-Executive Director
- Dr. Vimal ShrawatNon-Executive Director
- Mr. Suresh SinghNon-Executive Director
- Dr. Ravi BansalNon-Executive Independent Director
- Ms. Sangeeta BishnoiNon-Executive Independent Director
- Ms. Sumita DwivediNon-Executive Independent Director
- Mr. Sham GoelNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medicamen Biotech Ltd focuses on oncology therapeutics with key products like Abiraterone acetate and Anastrozole.
- The company manufactures diverse pharmaceutical formulations including tablets, capsules, and oncology injections for non-oncology segments.
- Medicamen Biotech employs 388 full-time staff in New Delhi, Delhi, supporting its manufacturing operations.
Weaknesses
- The company's product range is limited to non-oncology and oncology segments without expansion into other therapeutic areas.
- Medicamen Biotech lacks a presence in international markets beyond India, restricting global growth opportunities.
- Its focus on oncology therapeutics may increase vulnerability to market fluctuations in this specialized sector.
Opportunities
- Expanding into cardiology and central nervous system (CNS) therapeutic areas presents new market opportunities for Medicamen Biotech.
- The growing demand for oncology treatments in India offers significant growth potential for the company.
- Medicamen Biotech can leverage its existing manufacturing capabilities to enter emerging markets in Southeast Asia.
Threats
- Competition from established pharmaceutical companies in India poses a threat to Medicamen Biotech's market share.
- Regulatory changes in the Indian pharmaceutical sector could impact the company's operations and product approvals.
- Economic downturns in India may reduce healthcare spending, affecting demand for Medicamen Biotech's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.